This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ladányi, A. Articles by Tímár, J. Search for Related Content PubMed PubMed Citation Articles by Ladányi, A. Articles by Tímár, J.

T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma

¹ Departments of Tumor Progression and ² Dermatology and ³ National Cancer Registry, National Institute of Oncology, and ⁴ Institute of Dermato-Venerology, Semmelweis University, Budapest, Hungary

The central role of T cells in antitumor immunity is well established. However, tumor progression, often seen in the presence of substantial lymphocytic infiltration, suggests that these T cells are not capable of mounting an effective immune response to control tumor growth. Evidence has accumulated that T lymphocytes infiltrating human neoplasms are functionally defective, incompletely activated, or anergic. Therefore, when characterizing the immune competent cells within lymphoid infiltrates of tumors, it is important to assess their activation state. We investigated the expression of two T-cell activation markers, interleukin 2 receptor (CD25) and OX40 (CD134), by immunohistochemistry in primary cutaneous melanoma samples of 76 patients and analyzed it in relation to tumor stage and tumor progression (>5 years follow-up), as well as to patients’ survival. We found that the degree of infiltration by CD25⁺ and intratumoral OX40⁺ lymphocytes showed a tendency to decrease in thicker melanomas. The frequency of samples with high numbers of peritumoral CD25⁺ and OX40⁺ cells was significantly lower (P = 0.0009 and P = 0.0087, respectively) in melanomas developing distant visceral metastases, compared with nonmetastatic or lymph node metastatic tumors. For both activation markers studied, high peritumoral densities were associated with longer survival by univariate analysis (P = 0.0028 and P = 0.0255 for CD25 and OX40, respectively), whereas peritumoral OX40⁺ lymphocyte infiltration had an impact on survival also in multivariate analysis (P = 0.035). The results suggest that the presence of lymphocytes expressing the T-cell activation markers CD25 or OX40 shows correlation with tumor progression as well as with patients’ survival in cutaneous malignant melanoma.

This article has been cited by other articles:

				S. Ladoire, L. Arnould, L. Apetoh, B. Coudert, F. Martin, B. Chauffert, P. Fumoleau, and F. Ghiringhelli Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells Clin. Cancer Res., April 15, 2008; 14(8): 2413 - 2420. [Abstract] [Full Text] [PDF]

				C. Badoual, S. Hans, J. Rodriguez, S. Peyrard, C. Klein, N. E. H. Agueznay, V. Mosseri, O. Laccourreye, P. Bruneval, W. H. Fridman, et al. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers Clin. Cancer Res., January 15, 2006; 12(2): 465 - 472. [Abstract] [Full Text] [PDF]

				J. Timar, A. Ladanyi, C. Forster-Horvath, J. Lukits, B. Dome, E. Remenar, M. Godeny, M. Kasler, B. Bencsik, G. Repassy, et al. Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial J. Clin. Oncol., May 20, 2005; 23(15): 3421 - 3432. [Abstract] [Full Text] [PDF]

				Y. K. Chou, D. M. Edwards, A. D. Weinberg, A. A. Vandenbark, B. L. Kotzin, A. P. Fontenot, and G. G. Burrows Activation Pathways Implicate Anti-HLA-DP and Anti-LFA-1 Antibodies as Lead Candidates for Intervention in Chronic Berylliosis J. Immunol., April 1, 2005; 174(7): 4316 - 4324. [Abstract] [Full Text] [PDF]

				E. Ryschich, T. Notzel, U. Hinz, F. Autschbach, J. Ferguson, I. Simon, J. Weitz, B. Frohlich, E. Klar, M. W. Buchler, et al. Control of T-Cell-Mediated Immune Response by HLA Class I in Human Pancreatic Carcinoma Clin. Cancer Res., January 15, 2005; 11(2): 498 - 504. [Abstract] [Full Text] [PDF]